

100 वर्षों तक स्वस्थ, सुखी व सम्पन्न जीने के लिए





REGD OFFICE: SCO-11, Kalgidhar Enclave, Baltana, Zirakpur, Punjab-140604, 01762-513185 Branch: B-26, Opp. Metro Pillar No. 223, Rohtak Road, New Multan Nagar, Delhi - 110056

CIN NO.: L52601PB2017PLC046545

Email ID.: cs@jeenasikho.com

Date: October 03, 2024

To, The Manager- Listing **National Stock Exchange of India Limited** Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai-400 051

SYMBOL: JSLL; ISIN: INE0J5801011

Sub.: Outcome of Board Meeting and disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Dear Sir's.

This is to inform that the Board of Directors of Jeena Sikho Lifecare Limited ("the Company"), at its meeting held on Thursday, October 03, 2024, i.e., today, has, inter-alia, approved the acquisition and purchase of the Ayurveda Business of M/s. Oregano Life Private Limited, on a 'slump sale' basis as a going concern business, as per the terms and conditions of the binding Business Transfer Agreement executed between the Company and Oregano Life Private Limited on October 03, 2024.

The details, as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, for the aforesaid transaction is given as Annexure A.


The Board meeting commenced at 11:00 A.M. (IST) and concluded at 12:30 P.M. (IST).

We Request you to kindly take note of the same on record.

For Jeena Sikho Lifecare Limited

Manish Grover Managing Director DIN: 07557886

Encl: a.a.







Annexure A

SN	Disclosure	Information
1.	Name of the target entity, details in brief	Not applicable as no entity is being acquired.
	such as size, turnover etc.;	The transaction comprises of acquisition and purchase of the Ayurveda Business of M/s. Oregano Life Private Limited [CIN: U74999DL2020PTC370758] by our Company, on a 'slump sale' basis as a going concern business, as per the terms and conditions of the binding Business Transfer Agreement executed between the Company and Oregano Life Private Limited on October 03, 2024.
		Aforesaid Ayurveda Business acquired by the Company, comprises of the entire business of Oregano Life Private Limited relating to Ayurvedic Medicament, Panchkarma Medicines, Panchkarma and Ayurvedic Therapies (including Sirodhara, Abhyanga, Pathrapinda, Greevavasthi, Januvasthi etc.) from its various clinics, hospitals and Centres together with its respective assets, plant & machineries, lease rights, hospitals, clinics other Centres and also along with its associated goodwill and track records and with all facilities and also including employees/ contracts etc., pertaining to such Ayurveda Business and also including liabilities pertaining to the aforesaid and appearing in the books of accounts of the Ayurvedic Business. It, inter-alia comprises of hospitals/ Centres operating at following locations:
		 i. Krishan Kunj, Laxmi Nagar, Delhi ii. Mayur Vihar Phase 1, Delhi iii. Jhotwara, Jaipur, Rajasthan iv. Alwar, Rajasthan 301001 v. Gayatri Nagar, Tonk Road, Jaipur, Rajasthan
		Since this is an acquisition by slump sale, we understand that the details in brief such as size, turnover, etc. of Target Entity are not required to be disclosed.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof	No [The aforesaid transaction does not fall within related party transaction]

	and whether the same is done at "arm's	
	length"	
3.	Industry to which the entity being acquired belongs	Ayurveda health care and medicine
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Jeena Sikho Lifecare Limited a premier ayurveda health care and medicine enterprise in India. The present acquisition is with the objective of expansion of its business.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	N.A.
6.	Indicative time period for completion of the acquisition	Acquisition is completed and effective from 3 rd October, 2024
7.	Nature of consideration – whether cash consideration or share swap and details of the same	Cash consideration
8.	Cost of acquisition	Full and final consideration of Rs. 70.00 crores.
9.	Percentage of shareholding / control acquired and / or number of shares acquired	Not applicable as no acquisition of control/shares/voting rights is being contemplated.
10.	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information.	Not applicable as no entity acquisition is envisaged.